These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12026510)

  • 1. Are old drugs better than new?
    Gupta S
    Time; 2002 May; 159(19):89. PubMed ID: 12026510
    [No Abstract]   [Full Text] [Related]  

  • 2. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 3. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-marketing strategies for medicines.
    Breckenridge A
    Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug therapy].
    Aarbakke J; Rasmussen K
    Tidsskr Nor Laegeforen; 2003 Feb; 123(4):476-7. PubMed ID: 12643062
    [No Abstract]   [Full Text] [Related]  

  • 6. The latest trends in the pharmaceutical market.
    Teitelbaum F
    Case Manager; 2000; 11(5):70-4. PubMed ID: 11935588
    [No Abstract]   [Full Text] [Related]  

  • 7. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 8. Consumers' preferences for the communication of risk information in drug advertising.
    Davis JJ
    Health Aff (Millwood); 2007; 26(3):863-70. PubMed ID: 17485767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
    Patsner B
    Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
    [No Abstract]   [Full Text] [Related]  

  • 10. Beware of new drugs, study suggests.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 May; 13(10):1-2, 5. PubMed ID: 12492085
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant protein therapeutics--success rates, market trends and values to 2010.
    Pavlou AK; Reichert JM
    Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654
    [No Abstract]   [Full Text] [Related]  

  • 12. Are novel drugs more risky for patients than less novel drugs?
    Olson MK
    J Health Econ; 2004 Nov; 23(6):1135-58. PubMed ID: 15556240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs in 2001: a number of ruses unveiled.
    Prescrire Int; 2002 Apr; 11(58):58-60. PubMed ID: 11987319
    [No Abstract]   [Full Text] [Related]  

  • 14. New drugs: watch out for unexpected adverse effects.
    Prescrire Int; 2002 Oct; 11(61):150-1. PubMed ID: 12378747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J
    Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
    [No Abstract]   [Full Text] [Related]  

  • 16. The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
    Kesselheim AS; Fischer MA; Avorn J
    Health Aff (Millwood); 2006; 25(4):1095-102. PubMed ID: 16835191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk we bear: the effects of review speed and industry user fees on new drug safety.
    Olson MK
    J Health Econ; 2008 Mar; 27(2):175-200. PubMed ID: 18207263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maine law requires drug companies to provide clinical trial data.
    Appell D
    J Natl Cancer Inst; 2005 Sep; 97(17):1246. PubMed ID: 16145043
    [No Abstract]   [Full Text] [Related]  

  • 19. The origins of new drugs.
    Kneller R
    Nat Biotechnol; 2005 May; 23(5):529-30. PubMed ID: 15877061
    [No Abstract]   [Full Text] [Related]  

  • 20. The new drug evaluation process: risk benefit ratio.
    Somberg JC
    Am J Ther; 2005; 12(3):199-200. PubMed ID: 15891261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.